Project Grant K23AG088248
Award Date
8/15/24
Completion Date
5/31/29
Dollars Obligated
$198K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $106,464 to Brandeis University to conduct research on the associations between monoamine neurotransmitter systems, tau pathology, and emotional memory in aging. The research will utilize positron emission tomography (PET) imaging techniques to measure monoamine synthesis capacity and tau pathology in the brain, and relate these measures to performance on an emotional memory task. The findings...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will provide $203,278 to Brandeis University from November 2024 to January 2026 to conduct research on the neurobiological mechanisms underlying daily life activity participation in older adults and its relationship to Alzheimer's disease pathology. The project will use a multilevel, multimodal framework including behavioral, psychophysiological, neuroimaging, and naturalistic approaches to understand...
The National Institute on Aging (NIA) awarded a $137,895 Project Grant under the Aging Research federal grant program (CFDA 93.866) to the University of California, Berkeley (UC Berkeley) with a project period from December 3, 2024 to July 31, 2027. The grant will fund a study to investigate how brain network connectivity is associated with Alzheimer's disease (AD) risk, longitudinal pathology accumulation, and aging. Specifically, the project will use positron emission tomography (PET)...
This $208,750 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund a research project titled "Characterizing Autonomic Impairments in Frontotemporal Dementia" at The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The primary objectives are to: Assess the test-retest reliability of "gold-standard" measurements of autonomic function in 30 patients with behavioral variant frontotemporal...
This Federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $107,272 to Brandeis University to investigate the role of dopamine in reward memory processing in aging. The primary objectives are to: 1) Establish relationships between dopamine function and reward-related fMRI activation patterns during memory encoding, and 2) Link fMRI reinstatement, dopamine, and cognitive performance in older adults. The award period runs from Jan 3, 2025 to Jul...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) in the amount of $451,000 will fund a comprehensive evaluation of the phenomenology of rigid preoccupations (RP) in individuals with behavioral variant frontotemporal dementia (bvFTD) and semantic variant primary progressive aphasia (svPPA). The award will support a qualitative study to clarify the motivating emotions and thought processes underlying RP behaviors, as well as a retrospective chart...
This federal Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), provides $1,247,875 to Yale University to characterize the properties and performance of the PET radiotracer [18F]3F4AP for detecting and quantifying demyelination and cerebral perfusion in subjects with Alzheimer's disease (AD), mild cognitive impairment (MCI), and cognitively normal individuals. The research aims to perform the first full pharmacokinetic evaluation of...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,711,908 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the association between depressive symptoms and markers of neurodegeneration in individuals with mild cognitive impairment. The 5-year study aims to evaluate the relationship between cortico-limbic tau burden, cerebrovascular disease, and cognitive decline in participants with chronic late-life...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Aperture Therapeutics, Inc. in the amount of $459,525 provides funding to rapidly discover a novel oligonucleotide therapeutic for direct modulation of a genetically validated target involved in pathologic neuroinflammation associated with frontotemporal dementia (FTD) and related dementias. The project leverages Aperture's high-throughput iPSC platform with diverse genetic models of FTD to provide...
This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,173,794 to The General Hospital Corporation (Massachusetts General Hospital) to conduct research on enhancing brain resilience to Alzheimer's disease by targeting adult hippocampal neurogenesis. The project aims to explore the mechanisms by which adult hippocampal neurogenesis cooperates with brain-derived neurotrophic factor (BDNF) to potentially slow cognitive decline in...